233 related articles for article (PubMed ID: 30220530)
1. The mTOR-inhibitor Sirolimus decreases the cyclosporine-induced expression of the oncogene ATF3 in human keratinocytes.
Schaper-Gerhardt K; Walter A; Schmitz-Rode C; Satzger I; Gutzmer R
J Dermatol Sci; 2018 Nov; 92(2):172-180. PubMed ID: 30220530
[TBL] [Abstract][Full Text] [Related]
2. The oncogene ATF3 is potentiated by cyclosporine A and ultraviolet light A.
Dziunycz PJ; Lefort K; Wu X; Freiberger SN; Neu J; Djerbi N; Iotzowa-Weiss G; French LE; Dotto GP; Hofbauer GFL
J Invest Dermatol; 2014 Jul; 134(7):1998-2004. PubMed ID: 24509533
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus diminishes the expression of GRO-α (CXCL-1) /CXCR2 axis in human keratinocytes and cutaneous squamous cell carcinoma cells.
Schaper-Gerhardt K; Hansel A; Walter A; Grimmelmann I; Gutzmer R
J Dermatol Sci; 2021 Oct; 104(1):30-38. PubMed ID: 34479772
[TBL] [Abstract][Full Text] [Related]
4. Effects of mammalian target of rapamycin inhibitors on cytokine production and differentiation in keratinocytes.
DeTemple V; Satzger I; Walter A; Schaper K; Gutzmer R
Exp Dermatol; 2016 Oct; 25(10):775-82. PubMed ID: 27194247
[TBL] [Abstract][Full Text] [Related]
5. Differential induction of ATF3 and HO-1 in myeloid cells and keratinocytes via Dimethylfumarate or Cyclosporine A.
Müller S; Smatlik N; Burian M; Ghoreschi K; Röcken M; Yazdi AS
J Dermatol Sci; 2017 Sep; 87(3):246-251. PubMed ID: 28633807
[TBL] [Abstract][Full Text] [Related]
6. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
Leblanc KG; Hughes MP; Sheehan DJ
Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234
[TBL] [Abstract][Full Text] [Related]
7. Opposing roles for calcineurin and ATF3 in squamous skin cancer.
Wu X; Nguyen BC; Dziunycz P; Chang S; Brooks Y; Lefort K; Hofbauer GF; Dotto GP
Nature; 2010 May; 465(7296):368-72. PubMed ID: 20485437
[TBL] [Abstract][Full Text] [Related]
8. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control.
Connolly K; Manders P; Earls P; Epstein RJ
Cancer Treat Rev; 2014 Mar; 40(2):205-14. PubMed ID: 24051018
[TBL] [Abstract][Full Text] [Related]
9. UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer.
Liu-Smith F; Jia J; Zheng Y
Adv Exp Med Biol; 2017; 996():27-40. PubMed ID: 29124688
[TBL] [Abstract][Full Text] [Related]
10. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus and secondary skin-cancer prevention in kidney transplantation.
Euvrard S; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra AL; Hofbauer GF; Pouteil-Noble C; Campistol JM; Kanitakis J; Roux AS; Decullier E; Dantal J;
N Engl J Med; 2012 Jul; 367(4):329-39. PubMed ID: 22830463
[TBL] [Abstract][Full Text] [Related]
12. The secretome of skin cancer cells activates the mTOR/MYC pathway in healthy keratinocytes and induces tumorigenic properties.
Hoesl C; Zanuttigh E; Fröhlich T; Philippou-Massier J; Krebs S; Blum H; Dahlhoff M
Biochim Biophys Acta Mol Cell Res; 2020 Aug; 1867(8):118717. PubMed ID: 32283126
[TBL] [Abstract][Full Text] [Related]
13. Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes.
Xu S; Li L; Li M; Zhang M; Ju M; Chen X; Gu H
Oxid Med Cell Longev; 2017; 2017():5930639. PubMed ID: 28400912
[TBL] [Abstract][Full Text] [Related]
14. Activating transcription factor 3 (ATF3) expression is increased in erythema multiforme and is regulated by IFN-gamma in human keratinocytes.
Pollack BP; Sapkota B; Haun PL
Exp Dermatol; 2010 Aug; 19(8):e310-3. PubMed ID: 20002170
[TBL] [Abstract][Full Text] [Related]
15. Malignancies after heart transplantation: incidence, risk factors, and effects of calcineurin inhibitor withdrawal.
Doesch AO; Müller S; Konstandin M; Celik S; Kristen A; Frankenstein L; Ehlermann P; Sack FU; Katus HA; Dengler TJ
Transplant Proc; 2010 Nov; 42(9):3694-9. PubMed ID: 21094840
[TBL] [Abstract][Full Text] [Related]
16. Activation of renal profibrotic TGFβ controlled signaling cascades by calcineurin and mTOR inhibitors.
Eberhardt W; Nasrullah U; Pfeilschifter J
Cell Signal; 2018 Dec; 52():1-11. PubMed ID: 30145216
[TBL] [Abstract][Full Text] [Related]
17. Risk prediction tools for keratinocyte carcinoma after solid organ transplantation: a review of the literature.
Lowenstein SE; Garrett G; Toland AE; Jambusaria-Pahlajani A; Asgari MM; Green A; Engels EA; Arron ST;
Br J Dermatol; 2017 Nov; 177(5):1202-1207. PubMed ID: 28952162
[TBL] [Abstract][Full Text] [Related]
18. [Immunosuppressive drugs and the development of skin cancer after organ transplantation].
Gjersvik P; Helsing P; Holdaas H; Bergan S
Tidsskr Nor Laegeforen; 2012 Oct; 132(18):2064-8. PubMed ID: 23038197
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.
Dantal J; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; Del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra A; Hofbauer GFL; Kamar N; Pouteil-Noble C; Kanitakis J; Roux A; Decullier E; Euvrard S;
J Clin Oncol; 2018 Sep; 36(25):2612-2620. PubMed ID: 30016177
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin.
Dickinson SE; Janda J; Criswell J; Blohm-Mangone K; Olson ER; Liu Z; Barber C; Petricoin EF; Calvert VS; Einspahr J; Dickinson JE; Stratton SP; Curiel-Lewandrowski C; Saboda K; Hu C; Bode AM; Dong Z; Alberts DS; Timothy Bowden G
Cancer Prev Res (Phila); 2016 Mar; 9(3):215-24. PubMed ID: 26801880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
